FDA Advisers Meet Thursday on a Melanoma Therapy the Agency Says It Cannot Interpret

On the strength of that data, the FDA granted RP1 Breakthrough Therapy Designation and Priority Review, which are procedural recognitions of unmet need and promise rather than judgments about effectiveness. What the FDA Briefing Documents SayThis is where the meeting differs from a routine review, and it is why the article the desk assigned yesterday would have been outdated by publication. Trade coverage from BioSpace characterized the agency's position more bluntly, reporting that FDA described the data package as not interpretable. The National Cancer Institute and academic melanoma centers maintain trial listings, and a second opinion at a high-volume melanoma center is reasonable. What did the FDA briefing documents say?